Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes
复制标题
DOI：
10.1002/cpt.1319
复制
发表时间：
2019-06-01
影响因子：
6.7
通讯作者：
Biesecker, Leslie G.
中科院分区：
文献类型：
--
作者：
Gonsalves, Stephen G.;Dirksen, Robert T.;Biesecker, Leslie G.
在一名患者中鉴定出50个RYR1或CACNA1S基因变异中的1个，可以推断为恶性高热易感性（MHS）。MHS可导致对强效挥发性麻醉剂或琥珀酰胆碱的危及生命的反应。我们总结了文献中支持这种关联的证据，并提供了在RYR1或CACNA1S变异患者中使用这些药物的治疗建议（更新于和）。
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at and ).